Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 13.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between 18 and 45 years, inclusive.~* Good general health as determined by means of the screening procedure.~* Available for the duration of the trial (42 weeks).~* Willingness to participate in the study as evidenced by signing the informed consent document.~* If found to be infected with hookworm during screening, has completed a course of three doses of albendazole.~Exclusion Criteria:~* Pregnancy as determined by a positive urine β-hCG (if female).~* Participant unwilling to use reliable contraception methods up until one month following the third immunization (if female).~* Currently lactating and breast-feeding (if female).~* Inability to correctly answer all questions on the informed consent comprehension questionnaire.~* Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and/or laboratory studies.~* Known or suspected immunodeficiency.~* Laboratory evidence of liver disease (alanine aminotransferase \[ALT\] greater than 1.25-times the upper reference limit).~* Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than trace protein or blood on urine dipstick testing).~* Laboratory evidence of hematologic disease (absolute leukocyte count \<3000/mm3 or \>12.5 x 103/mm3; hemoglobin \<10.3 g/dl or \<11.0 g/dl \[females in Americaninhas and Belo Horizonte, respectively\] or \<11.0 g/dl or \<12.0 \[males in Americaninhas and Belo Horizonte, respectively); absolute lymphocyte count \<900/mm3; or platelet count \<120,000/mm3).~* Laboratory evidence of a coagulopathy (PTT or PT INR greater than 1.1-times the upper reference limit \[in Belo Horizonte\] or PT INR greater than 1.3 \[Americaninhas\]).~* Serum glucose (random) greater than 1.2-times the upper reference limit.~* Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.~* Participation in another investigational vaccine or drug trial within 30 days of starting this study.~* Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.~* History of a severe allergic reaction or anaphylaxis.~* Severe asthma as defined by the need for regular use of inhalers or emergency clinic visit or hospitalization within the last 6 months.~* Positive ELISA for HCV.~* Positive ELISA for HBsAg.~* Positive ELISA for HIV.~* Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of starting this study.~* Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks prior to entry into the study.~* History of a surgical splenectomy.~* Receipt of blood products within the past 6 months.~* History of allergy to yeast.~* Anti-Na-GST-1 IgE antibody level above 0.35 kUA/L by the ImmunoCAP method.~* For Part I only: history of previous infection with hookworm; residence for more than 6 months in a hookworm-endemic area; or, positive for hookworm infection on screening microscopic fecal examination.~* For Part II only: previous receipt of a primary series of any hepatitis B vaccine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Part I-A: 10μgNaGST1/Alhydrogel (Type: EXPERIMENTAL): Part I (non-endemic area), Formulation A
- Part I-B: 30μgNaGST1/Alhydrogel (Type: EXPERIMENTAL): Part I (non-endemic area), Formulation B
- Part I-C: 100μgNaGST1/Alhydrogel (Type: EXPERIMENTAL): Part I (non-endemic area), Formulation C
- Part I-D: 10μgNaGST1/Alhydrogel/GLA (Type: EXPERIMENTAL): Part I (non-endemic area), Formulation D
- Part I-E: 30μgNaGST1/Alhydrogel/GLA (Type: EXPERIMENTAL): Part I (non-endemic area), Formulation E
- Part I-F: 100μgNaGST1/Alhydrogel/GLA (Type: EXPERIMENTAL): Part I (non-endemic area), Formulation F
- Part II-A: 10μgNaGST1/Alhydrogel (Type: EXPERIMENTAL): Part II (endemic area), Formulation A
- Part II-B: 30μgNaGST1/Alhydrogel (Type: EXPERIMENTAL): Part II (endemic area), Formulation B
- Part II-C: 100μgNaGST1/Alhydrogel (Type: EXPERIMENTAL): Part II (endemic), Formulation C
- Part II-D: 10μgNaGST1/Alhydrogel/GLA (Type: EXPERIMENTAL): Part II (endemic area), Formulation D
- Part II-E: 30μgNaGST1/Alhydrogel/GLA (Type: EXPERIMENTAL): Part II (endemic area), Formulation E
- Part II-F: 100μgNaGST1/Alhydrogel/GLA (Type: EXPERIMENTAL): Part II (endemic area), Formulation F
- Part II-G: Butang® hepatitis B vaccine (Type: ACTIVE_COMPARATOR): Part II (endemic), HepB comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).